{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:23:48Z","timestamp":1781886228231,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Besides distinctive respiratory and digestive hallmarks, COVID-19 has been recently associated with a high prevalence of pro-inflammatory and hypercoagulable states known as \u201cCOVID-19 Associated Coagulopathy\u201d (CAC), corresponding to a worsening in patients\u2019 conditions, whose causes are still to be elucidated. A link between anti-phospholipid antibodies (aPLs) and viral infections has long been suggested. APLs are assessed for anti-phospholipid syndrome (APS) diagnosis, characterized by thrombocytopenia, thrombosis, and coagulopathy. Furthermore, circulating immune complexes (CICs), arisen upon inflammatory responses and related immune dysregulation, can lead to endothelial cell damage and thrombotic complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We performed an extended panel including IgG\/IgM anti-cardiolipin, IgG\/IgM anti-\u03b22-glycoprotein-1, coupled with IgG\/IgM anti-prothrombin, IgG\/IgM anti-annexin-V on two COVID-19 patient groups (early and late infection time), and a negative control group. IgG CIC analysis followed to evaluate inflammatory status, through a possible complement system activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results showed low positive case percentage in IgG\/IgM anti-cardiolipin and IgG\/IgM anti-\u03b22-glycoprotein-1 assays (4.54%, 6.25%, and 4.55%; in early infection group, late infection group, and control group, respectively); few positive cases in IgG\/IgM anti-prothrombin and IgG\/IgM anti-annexin-V immunoassays; and no IgG CIC positivity in any patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In conclusion, our data show a low aPL prevalence, likely excluding an involvement in the pathogenesis of CAC. Interestingly, IgG\/IgM anti-prothrombin and anti-annexin-V positive cases, detected in late infection group, suggest that aPLs could temporarily increase or could trigger a \u201cCOVID-19-induced-APS-like-syndrome\u201d in predisposed patients.\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                <jats:bold>\u2022<\/jats:bold>\n                                <jats:italic>To our knowledge, anti-prothrombin (aPT) antibodies, anti-annexin-V antibodies and CICs in COVID-19 patients have not been reported in the scientific literature.<\/jats:italic>\n                                <jats:bold>\u2022<\/jats:bold>\n                                <jats:italic>Lack of uniformity and the low percentage of aCL\/a\u03b22GP1 positivity preclude a putative role in CAC pathogenesis.<\/jats:italic>\n                                <jats:bold>\u2022<\/jats:bold>\n                                <jats:italic>IgG\/IgM anti-prothrombin and IgG\/IgM anti-annexin-V data show that distribution of positive case number increases in late infection patients, significantly in anti-annexin-V results, suggesting a possible role for these anti-phospholipid antibodies in disease course.<\/jats:italic>\n                                <jats:bold>\u2022<\/jats:bold>\n                                <jats:italic>aPLs can arise transiently in some patients with critical illness and SARS-CoV-2 infection (disappearing in a few weeks), as well as in other genetically predisposed patients; they could trigger a \u201cCOVID-19-induced-APS-like-syndrome\u201d.<\/jats:italic>\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-021-05580-3","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:02:53Z","timestamp":1611014573000},"page":"2939-2945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Anti-phospholipids antibodies and immune complexes in COVID-19 patients: a putative role in disease course for anti-annexin-V antibodies"],"prefix":"10.1007","volume":"40","author":[{"given":"Antonio","family":"Cristiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Fortunati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cherubini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Nuccetelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"issue":"3","key":"5580_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","volume":"27","author":"A Wu","year":"2020","unstructured":"Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J, Sheng J, Quan L, Xia Z, Tan W, Cheng G, Jiang T (2020) Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27(3):325\u2013328. https:\/\/doi.org\/10.1016\/j.chom.2020.02.001","journal-title":"Cell Host Microbe"},{"issue":"8","key":"5580_CR2","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/jth.14888","volume":"18","author":"S Middeldorp","year":"2020","unstructured":"Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, M\u00fcller MCA, Bouman CCS, Beenen LFM, Kootte RS, Heijmans J, Smits LP, Bonta PI, van Es N (2020) Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 18(8):1995\u20132002. https:\/\/doi.org\/10.1111\/jth.14888","journal-title":"J Thromb Haemost"},{"issue":"9","key":"5580_CR3","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1097\/CCM.0000000000004458","volume":"48","author":"T Iba","year":"2020","unstructured":"Iba T, Levy JH, Levi M, Connors JM, Thachil J (2020) Coagulopathy of coronavirus disease 2019. Crit Care Med 48(9):1358\u20131364. https:\/\/doi.org\/10.1097\/CCM.0000000000004458","journal-title":"Crit Care Med"},{"issue":"4","key":"5580_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M20-2003","volume":"173","author":"D Wichmann","year":"2020","unstructured":"Wichmann D, Sperhake JP, L\u00fctgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schr\u00f6der AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, P\u00fcschel K, Kluge S (2020) Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 173(4):268\u2013277. https:\/\/doi.org\/10.7326\/M20-2003","journal-title":"Ann Intern Med"},{"issue":"5","key":"5580_CR5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.7326\/M20-2566","volume":"173","author":"SF Lax","year":"2020","unstructured":"Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, Vander K, Bargfrieder U, Trauner M (2020) Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med 173(5):350\u2013361. https:\/\/doi.org\/10.7326\/M20-2566","journal-title":"Ann Intern Med"},{"issue":"2","key":"5580_CR6","doi-asserted-by":"publisher","DOI":"10.1148\/ryct.2020200067","volume":"2","author":"Y Xie","year":"2020","unstructured":"Xie Y, Wang X, Yang P, Zhang S (2020) COVID-19 Complicated by acute pulmonary embolism. Radiol Cardiothorac Imaging 2(2):e200067. https:\/\/doi.org\/10.1148\/ryct.2020200067","journal-title":"Radiol Cardiothorac Imaging"},{"issue":"7","key":"5580_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/jmv.25770","volume":"92","author":"Y Gao","year":"2020","unstructured":"Gao Y, Li T, Han M, Li X, Wu D, Xu Y, Zhu Y, Liu Y, Wang X, Wang L (2020) Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 92(7):791\u2013796. https:\/\/doi.org\/10.1002\/jmv.25770","journal-title":"J Med Virol"},{"issue":"5","key":"5580_CR8","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130(5):2620\u20132629. https:\/\/doi.org\/10.1172\/JCI137244","journal-title":"J Clin Invest"},{"issue":"23","key":"5580_CR9","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2020006000","volume":"135","author":"JM Connors","year":"2020","unstructured":"Connors JM, Levy JH (2020) COVID-19 and its implications for thrombosis and anticoagulation. Blood 135(23):2033\u20132040. https:\/\/doi.org\/10.1182\/blood.2020006000","journal-title":"Blood"},{"issue":"7","key":"5580_CR10","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1111\/jth.14854","volume":"18","author":"M Ranucci","year":"2020","unstructured":"Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, Falco M, Albano G, Menicanti L (2020) The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 18(7):1747\u20131751. https:\/\/doi.org\/10.1111\/jth.14854","journal-title":"J Thromb Haemost"},{"issue":"4","key":"5580_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood.2020006520","volume":"136","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, Goodarzi K, Bendapudi PK, Bornikova L, Gupta S, Leaf DE, Kuter DJ, Rosovsky RP (2020) COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 136(4):489\u2013500. https:\/\/doi.org\/10.1182\/blood.2020006520","journal-title":"Blood."},{"issue":"1","key":"5580_CR12","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1038\/s41598-018-20947-4","volume":"8","author":"C Thanadetsuntorn","year":"2018","unstructured":"Thanadetsuntorn C, Ngamjanyaporn P, Setthaudom C, Hodge K, Saengpiya N, Pisitkun P (2018) The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus. Sci Rep 8(1):2620. https:\/\/doi.org\/10.1038\/s41598-018-20947-4","journal-title":"Sci Rep"},{"issue":"17","key":"5580_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2007575","volume":"382","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, Zhao J, Sun X, Tian R, Wu W, Wu D, Ma J, Chen Y, Zhang D, Xie J, Yan X, Zhou X, Liu Z, Wang J, Du B, Qin Y, Gao P, Qin X, Xu Y, Zhang W, Li T, Zhang F, Zhao Y, Li Y, Zhang S (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382(17):e38. https:\/\/doi.org\/10.1056\/NEJMc2007575","journal-title":"N Engl J Med"},{"issue":"8","key":"5580_CR14","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1111\/jth.14867","volume":"18","author":"I Harzallah","year":"2020","unstructured":"Harzallah I, Debliquis A, Dr\u00e9nou B (2020) Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost 18(8):2064\u20132065. https:\/\/doi.org\/10.1111\/jth.14867","journal-title":"J Thromb Haemost"},{"key":"5580_CR15","doi-asserted-by":"publisher","unstructured":"Connell NT, Battinelli EM, Connors JM (2020) Coagulopathy of COVID-19 and antiphospholipid antibodies. J Thromb Haemost 10.1111\/jth.14893. doi: https:\/\/doi.org\/10.1111\/jth.14893","DOI":"10.1111\/jth.14893"},{"key":"5580_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.thromres.2020.05.017","volume":"192","author":"F Galeano-Valle","year":"2020","unstructured":"Galeano-Valle F, Oblitas CM, Ferreiro-Maz\u00f3n MM, Alonso-Mu\u00f1oz J, Del Toro-Cervera J, di Natale M, Demelo-Rodr\u00edguez P (2020) Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res 192:113\u2013115. https:\/\/doi.org\/10.1016\/j.thromres.2020.05.017","journal-title":"Thromb Res"},{"key":"5580_CR17","doi-asserted-by":"publisher","first-page":"584241","DOI":"10.3389\/fimmu.2020.584241","volume":"11","author":"MO Borghi","year":"2020","unstructured":"Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C, Grossi C, Blengino S, Tincani A, Franceschini F, Andreoli L, Lazzaroni MG, Piantoni S, Masneri S, Crisafulli F, Brugnoni D, Muiesan ML, Salvetti M, Parati G, Torresani E, Mahler M, Heilbron F, Pregnolato F, Pengo M, Tedesco F, Pozzi N, Meroni PL (2020) Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunol 11:584241. https:\/\/doi.org\/10.3389\/fimmu.2020.584241","journal-title":"Front Immunol"},{"issue":"9","key":"5580_CR18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1111\/jth.14994","volume":"18","author":"KMJ Devreese","year":"2020","unstructured":"Devreese KMJ, Linskens EA, Benoit D, Peperstraete H (2020) Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost 18(9):2191\u20132201. https:\/\/doi.org\/10.1111\/jth.14994","journal-title":"J Thromb Haemost"},{"issue":"2","key":"5580_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/antib5020015","volume":"5","author":"KJ Lackner","year":"2016","unstructured":"Lackner KJ, M\u00fcller-Calleja N (2016) Antiphospholipid antibodies: their origin and development. Antibodies (Basel) 5(2):15. https:\/\/doi.org\/10.3390\/antib5020015","journal-title":"Antibodies (Basel)"},{"issue":"12","key":"5580_CR20","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/art.41425","volume":"72","author":"M Xiao","year":"2020","unstructured":"Xiao M, Zhang Y, Zhang S, Qin X, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, Zhao J, Sun X, Tian R, Wu W, Wu D, Ma J, Chen Y, Zhang D, Xie J, Yan X, Zhou X, Liu Z, Wang J, Du B, Qin Y, Gao P, Lu M, Hou X, Wu X, Zhu H, Xu Y, Zhang W, Li T, Zhang F, Zhao Y, Li Y, Zhang S (2020) Antiphospholipid antibodies in critically ill patients with COVID-19. Arthritis Rheumatol 72(12):1998\u20132004. https:\/\/doi.org\/10.1002\/art.41425","journal-title":"Arthritis Rheumatol"},{"key":"5580_CR21","doi-asserted-by":"publisher","unstructured":"Zuo Y, Estes SK, Gandhi AA, Yalavarthi S, Ali RA, Shi H, Sule G, Gockman K, Madison JA, Zuo M, Woodard W, Lezak SP, Lugogo NL, Kanthi Y, Knight JS (2020) Prothrombotic antiphospholipid antibodies in COVID-19. medRxiv [Preprint]. 2020.06.15.20131607. doi: https:\/\/doi.org\/10.1101\/2020.06.15.20131607","DOI":"10.1101\/2020.06.15.20131607"},{"issue":"3","key":"5580_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3892\/ijmm.2020.4659","volume":"46","author":"E Cavalli","year":"2020","unstructured":"Cavalli E, Bramanti A, Ciurleo R, Tchorbanov AI, Giordano A, Fagone P, Belizna C, Bramanti P, Shoenfeld Y, Nicoletti F (2020) Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: diagnostic and therapeutic perspectives (Review). Int J Mol Med 46(3):903\u2013912. https:\/\/doi.org\/10.3892\/ijmm.2020.4659","journal-title":"Int J Mol Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05580-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05580-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05580-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T12:10:16Z","timestamp":1623240616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05580-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["5580"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05580-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-86353\/v1","asserted-by":"object"}]},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"29 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"All samples were recovered in accordance with local ethical approvals (R.S.44.20), from \u201cTor Vergata\u201d University COVID-Hospital of Rome.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all subjects enrolled in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from all subjects enrolled in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}